中国血液净化

›› 2002, Vol. 1 ›› Issue (9): 29-30.

• 论著 • 上一篇    下一篇

优思弗联合人工肝治疗慢性重型肝炎的临床观察

陈 晓 常德成 韩大康 刘义荣 段钟平   

  1. 100054 北京，北京佑安医院，首都医科大学传染病寄生虫病教研室
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2002-09-19 发布日期:2002-09-19

  • Received:1900-01-01 Revised:1900-01-01 Online:2002-09-19 Published:2002-09-19

RichHTML

0

PDF

175

摘要： [摘要]目的 评价熊去氧胆酸（Ursodeoxycholic acid, UDCA,优思弗）联合人工肝治疗慢性重型肝炎的疗效及安全性。方法 慢性重型肝炎64例，随机分为治疗组32例，对照组32例。治疗组应用优思弗联合人工肝及综合疗法治疗，对照组32例，仅用综合疗法治疗。结果 治疗组患者肝功能检查指标均有显著改善。根据疗效判断标准，在其4周时显效率为46.9%，有效率为25.0%，无效率为28.1%，总有效率为71.9%，与对照组相比P〈0.05。结论 优思弗联合人工肝治疗慢性重型肝炎是安全和有效的。

关键词: 熊去氧胆酸, 人工肝, 慢性重型肝炎

Abstract: [Abstract] Objective To evaluate the efficacy and safety of Ursofalk (UDCA) and artificial liver support system in treatment of chronic sever hepatitis. Methods 64 patients with chronic severe hepatitis were randomly divided into two groups : the treated group of 32 cases and the control group of 32 cases. The treatment group was treated with Ursofalk and artificial support systems in addition to conventional therapy. The control group was only treated with conventional therapy. Results In treated group,liver functions of the patients improved significantly (P<0.05). The markedly effective rate at 4 weeks was 46.9%, effective rate was 25.0%, and the total effective rate was 71.9%. There was significant difference between the two groups (P<0.05). Conclusion Ursofalk combined with artificial liver treatment and conventional therapy is safe and more effective in treatment of chronic severe hepatitis.

Key words: Artificial liver, Chronic severe hepatitis